Topic:

Facilities

Latest Headlines

Latest Headlines

Lilly to cut 100 production jobs in Indianapolis, but workers get shot at others

Eli Lilly says about 100 jobs will be lost in its dry products operations as it rejiggers tablet and capsule production over the next several years, but that employees will have the chance to move to other positions, like in its growing insulin operations.

Aptuit putting $1M into cytotoxic capabilities in Scotland

Contract services company Aptuit will invest $1 million in its facility in Glasgow, Scotland, to expand its capacity to manufacture sterile cytotoxic liquid and lyophilized drug products.

J&J improves McNeil unit sales even as key plant remains closed for remediation

Johnson & Johnson has managed a turnaround in its McNeil Consumer Health division by producing products like Tylenol and Motrin at facilities other than its still-closed Fort Washington, PA, plant and getting them back on retailer's shelves.

Pfizer and Sun snatch up sterile injectable companies to boost expertise and capacity

The sterile injectables business holds promise for drugmakers with the manufacturing capabilities to produce the difficult-to-make drugs. Deals announced Wednesday by Pfizer and Sun Pharma were proof positive of how companies think they can cash in on the generics piece of this sterile injectables market.

Purdue moves forward with $59M plant in North Carolina

Purdue Pharma will build a new $59 million plant in Durham, NC, and has awarded a contract to KBR Building Group to erect the 188,000-square-foot facility.

Glenmark to build $100M plant in North America

Glenmark has more than a dozen manufacturing plants around the world, recently opening a mAb manufacturing facility in Switzerland to feed its pipeline of monoclonal antibodies and biosimilars. But the Indian generics maker does not have a plant in North America and figures it is time.

Job-cutting Pfizer saves 100 jobs in Ireland

Pfizer has a reputation for being a company that will cut jobs deeply once a merger is done, a rap that raised a lot of fears during its run at AstraZeneca. But the U.S. drugmaker can now point to about 100 jobs in Ireland that it is sparing as business has improved.

Novo A/S-owned Xellia snaps up Fresenius vial plant to expand in U.S.

The deal gives Xellia capacity in North America for the first time, providing the company with a platform from which to realize the mid-term growth opportunities envisaged by Novo A/S when it bought the company.

Hospira completes Orchid plant takeover to boost API supply security

The $218 million takeover gives Hospira an API plant and 665 staff in Aurangabad, India, furthering its ambition to become less reliant on third-party ingredient suppliers.

Health Canada gives GSK 30 days to show how it will fix its vaccine plant

Having spent the past few months trying to bring standards at its Quebec City vaccine plant in line with FDA expectations, GlaxoSmithKline must now work to satisfy another regulator: Health Canada. The Canadian regulator sent GSK an inspection report late last week and gave the Big Pharma 30 days to come up with a plan to fix the problems faced by the facility.